Cannabis and Essential Tremor

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

Plain-language summary

Essential tremor (ET) is a neurological condition that causes rhythmic shaking, usually in the hands, typically worse during intentional movement — like writing, lifting a cup, or pointing. It is distinct from Parkinson's tremor, which occurs at rest.

Standard first-line treatments are the beta-blocker propranolol and the anticonvulsant primidone. Each reduces tremor amplitude by roughly 50% in people who respond to them, though about half of ET patients get insufficient benefit or experience side effects like fatigue or low blood pressure ^[1].

Cannabis is frequently discussed in online ET communities and by patients exploring options because (a) the endocannabinoid system is involved in motor control, (b) laboratory studies show THC and CBD can reduce tremor in some animal models, and (c) anecdotal reports are common. The controlled human evidence, however, is much more cautious: there are very few rigorous trials of cannabis in ET specifically, and the most rigorous trial conducted — a randomized, placebo-controlled test of pure CBD — did not show benefit ^[2].

This article is not medical advice. Essential tremor can overlap with other neurological conditions. Cannabis interacts with many medications, especially those metabolized by the liver. Decisions about adding cannabis to your ET treatment should involve a qualified neurologist who knows your full medical history.

What probably works (strong evidence)

Nothing in the cannabis space currently meets a 'strong evidence' bar for essential tremor. No data

No cannabinoid — not THC alone, not CBD alone, not nabiximols (THC+CBD combination), not synthetic analogs — has been shown in adequately powered, replicated, randomized controlled trials to reduce tremor in essential tremor patients when measured on standardized clinical scales.

If you encounter a dispensary, clinic, influencer, or product page claiming cannabis is a 'proven treatment' for ET, that claim exceeds what the published evidence supports.

What might work (weak or preliminary evidence)

THC-containing cannabis, subjective improvement. Patient surveys document that a meaningful minority of people with ET who use cannabis report subjective tremor reduction or improved function. A 2022 survey of ET patients found a substantial fraction of users reporting benefit. However, these are self-reports collected after the fact, without blinding or objective tremor measurement. Weak / limited

Subjective improvement does not equal measured tremor reduction. Expectancy, placebo effect, and anxiety relief (see below) all contribute to subjective reports and are not ruled out in survey data.

Anxiety reduction and tremor amplification. Essential tremor often worsens in stressful or social situations due to anxiety-driven nervous system activation. Cannabis — particularly low-dose THC or CBD — may reduce the anxiety component that amplifies tremor during public activities (speaking, eating in front of others), without directly affecting the underlying tremor mechanism. This is biologically plausible but has not been formally measured in ET trials. Weak / limited

Endocannabinoid system and motor circuits. Preclinical research shows cannabinoid CB1 receptors are present in the cerebellum and inferior olive, brain regions implicated in essential tremor ^[3]. Cannabinoid agonists reduce tremor in some animal models, such as harmaline-induced tremor in rodents. This is mechanistic rationale for why cannabis might theoretically help, but animal tremor models do not reliably translate to human disease benefit. Weak / limited

If you are considering a trial of cannabis for ET on these grounds, treat it as a personal experiment. Ideally, track objective measurements: video-record standardized tasks (e.g., holding a pen steady, drinking from a cup) before and after use, or use a smartphone accelerometer app to quantify tremor amplitude. Subjective feeling better is useful information, but it is not the same as reduced tremor.

What doesn't work / negative evidence

Pure CBD alone. A 2022 randomized, double-blind, placebo-controlled crossover trial enrolled adults with essential tremor and tested escalating doses of CBD (up to 300 mg/day) versus placebo. The trial was modest in size but methodologically sound. CBD did not significantly reduce tremor amplitude or functional impairment compared to placebo on standardized rating scales (Fahn-Tolosa-Marin Tremor Rating Scale) ^[2]. Strong evidence

This negative finding is important because CBD is what most people with ET try first — it is legal, widely available, and heavily marketed for neurological conditions, including tremor. The best-controlled evidence available for CBD monotherapy at clinically relevant doses says: no benefit beyond placebo in essential tremor.

'Indica strains reduce tremor, sativa strains worsen it.' The cannabis classification system into 'indica' and 'sativa' based on plant morphology does not reliably predict cannabinoid content or effects in humans ^[4]. Any specific claim that an 'indica' strain is anti-tremor while a 'sativa' is not is folklore unsupported by pharmacology. No data

High-CBD topical creams for tremor. Tremor is a central nervous system phenomenon — it arises from circuits in the brain and cerebellum. Topical CBD does not cross the blood–brain barrier in meaningful concentrations and therefore has no plausible mechanism to reduce tremor. No data

What we don't know

• THC monotherapy in essential tremor. No adequately powered randomized trial has tested THC alone (or THC-dominant products) in ET patients. The one negative CBD trial did not include THC. Whether THC as monotherapy or in combination might work is untested.
• CBD + THC combinations (nabiximols). Nabiximols (Sativex) is a pharmaceutical spray combining THC and CBD. It has been studied for tremor in multiple sclerosis, with mixed and modest results — but MS tremor is a different neurological condition arising from demyelinating pathology. Whether the combination works in ET specifically is unknown.
• Optimal dosing, route, and timing. No dose-escalation studies in ET. No comparison of inhaled versus oral. No data on timing relative to meals, activity, or other medications.
• Responder characteristics. Do people whose ET improves subjectively with cannabis share any clinical features (age, disease severity, baseline anxiety, genetic markers) that predict response?
• Long-term safety and efficacy. Most ET patients are older adults (median age >50). Long-term data on cannabis use in this population — particularly regarding cognition, balance, cardiovascular effects, and medication interactions — is sparse.
• Interaction pharmacokinetics. Primidone and propranolol are metabolized through liver cytochrome P450 enzymes. CBD inhibits some of these same enzymes. The clinical significance of co-dosing these drugs at typical doses has not been formally studied.

Comparison with standard and alternative treatments

First-line pharmacotherapy (propranolol, primidone). Both have decades of clinical evidence and are recommended in the American Academy of Neurology guideline for essential tremor ^[1]. Propranolol (a non-selective beta-blocker) and primidone (an anticonvulsant) each reduce tremor amplitude by approximately 50% in patients who respond. However, roughly half of ET patients achieve insufficient benefit or experience limiting side effects (fatigue, orthostatic hypotension, sedation, cognitive dulling). These drugs have well-characterized pharmacokinetics and safety profiles in older adults.

Second-line oral options. Topiramate, gabapentin, and benzodiazepines (clonazepam) have moderate evidence for efficacy in ET and are used when first-line agents fail or cause intolerance.

Procedural interventions. For severe, drug-refractory ET:

• Deep brain stimulation (DBS) of the thalamus produces large, durable tremor reduction (typically 80–90% improvement) with reversibility if complications occur ^[5].
• MR-guided focused ultrasound (MRgFUS) thalamotomy ablates a small thalamic region with precise imaging guidance, producing substantial tremor reduction (70–80% in published trials) with permanent effect ^[5].

Both DBS and MRgFUS are far more effective than any oral pharmacotherapy or cannabis in severe, functional tremor.

Cannabis (THC, CBD, or combinations). Sits below all of the above in the evidence hierarchy for essential tremor. It is not an established treatment. At best, it is speculative as an adjunct that might benefit some individuals, with the strong caveat that the one rigorous trial was negative and longer-term, larger trials are lacking.

Risks and interactions

• Cognitive and balance effects. Older adults — who comprise the majority of ET patients — are more sensitive to THC's effects on cognition (memory, processing speed), balance, and cardiovascular reflexes. Falls are a real safety concern in an elderly population already at risk for falls due to tremor itself.

• Potential tremor worsening. THC at higher doses can occasionally produce or amplify tremor or jitteriness, particularly in people who are inexperienced with cannabis or sensitive to its acute effects Weak / limited. The mechanism is unclear but may involve central nervous system excitation.

• Liver enzyme interactions. CBD is metabolized by and inhibits cytochrome P450 enzymes — particularly CYP3A4, CYP2C19, and CYP1A2 ^[6]. Primidone metabolism involves these same pathways. High-dose CBD could raise primidone levels, increasing toxicity (sedation, ataxia, cognitive effects). This combination has not been studied clinically. Propranolol metabolism is less dependent on these enzymes, but interaction cannot be ruled out.

• Cardiovascular effects. THC raises heart rate and sympathetic tone acutely and can worsen orthostatic hypotension — a particular concern in older adults and in those already taking propranolol (which lowers blood pressure and heart rate). Combined use could theoretically lead to blood pressure instability.

• Psychiatric effects. THC can trigger or worsen anxiety, paranoia, or depressive symptoms in susceptible individuals. Anxiety amplifies ET; paradoxically, THC use intended to reduce tremor could worsen it through anxiety induction.

• Cannabis-induced anxiety. Some people experience increased anxiety or panic with THC use, particularly at higher doses or with THC-dominant products. See Cannabis-Induced Anxiety for more detail.

• Product quality and labeling accuracy. In unregulated or lightly regulated markets, cannabinoid content on product labels frequently does not match laboratory analysis ^[7]. Inconsistency in dose makes safety and efficacy assessment impossible. Medical cannabis products in regulated jurisdictions tend to be more reliable but are costly and often not covered by insurance.

• Dependence and withdrawal. Regular cannabis use can lead to dependence; abrupt cessation can produce irritability, anxiety, and sleep disruption — which may amplify tremor in the short term.

Medication interaction considerations

Essential tremor patients often take propranolol or primidone. Cannabis, particularly CBD-rich products, introduces several pharmacokinetic and pharmacodynamic interaction risks:

CYP450 enzyme inhibition. CBD inhibits CYP3A4 and CYP2C19, which metabolize primidone ^[6]. This could raise primidone blood levels and increase side effects. Propranolol is less dependent on these enzymes but can still be affected.

Additive CNS depression. Both primidone and benzodiazepines (used in some ET patients) are sedating. Cannabis adds to this effect.

Cardiovascular. Propranolol and THC have opposing cardiovascular effects (beta-blockade vs. sympathomimetic); the clinical outcome is unpredictable.

Before adding cannabis to an existing ET regimen, discuss with a neurologist and pharmacist. Blood levels of primidone may need monitoring if you do combine drugs.

For more detail, see Cannabis and Polypharmacy Risks.

Summary and clinical takeaway

Essential tremor is treatable; effective options exist across a spectrum of evidence and invasiveness:

1. First-line pharmacotherapy (propranolol, primidone) is established and helps roughly half of patients.
2. Procedural options (DBS, MRgFUS) produce the largest and most durable tremor reductions and are appropriate for severe, drug-refractory cases.
3. Cannabis has minimal rigorous evidence. One well-designed CBD trial was negative. Anecdotal reports of benefit exist but are not confirmed by objective measurement in controlled settings. THC is largely unstudied in ET.

If you are considering cannabis for essential tremor:

• Do not expect it to be a primary treatment or replacement for propranolol or primidone.
• Discuss it explicitly with your neurologist, including potential interactions with your current medications.
• If you do trial cannabis, use objective measures (video, tremor app) to assess actual tremor change, not just subjective feeling.
• Be aware of safety risks, particularly if you are older, taking other CNS-active drugs, or at risk for falls.
• Purchase from a regulated source with verified labeling if possible.

This article is not medical advice. It summarizes published evidence for educational purposes. Decisions about treating essential tremor, whether with cannabis or any other intervention, should be made with a qualified neurologist who understands your full clinical context, comorbidities, and medication list.

Sources

How this page was made

Related

• Cannabis and Parkinson's Tremor — Cannabinoids show weak evidence for motor tremor; possible benefit for non-motor symptoms...
• Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
• Cannabis for Tremor — An honest look at what cannabis can and can't do for essential tremor, Parkinson's tremor,...
• Cannabis-Induced Anxiety — How THC dose, individual vulnerability, and setting trigger acute anxiety; what actually h...
• THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...